Top
image credit: Maxpixel

New malaria vaccine shows high efficacy, yields high hopes

September 8, 2022

Category:

Hopes were already running high for the R21/Matrix-M vaccine, after it showed 77% protective efficacy over 12 months in a phase 2b trial involving young west African children – meeting the World Health Organization’s efficacy goal of 75% – after an initial three-dose course of injections, as reported last year.

Now, the 450-patient study has follow-up data from a group of 409 children who received a fourth booster dose at one year, with either a low (25 μg) or high (50 μg) dose of Novavax’ Matrix-M adjuvant, used to boost the immune response to the R21 antigen.

Read More on Pharmaphorum